Postmenopausal Bleeding Is Never "Just Hormones"

By Daniel Soule, Owner and Clinic Director, HormoneSynergy®

One of the more concerning conversations in menopause care begins with a sentence clinicians hear often: “I assumed it was just my hormones.”

Hormone therapy can affect bleeding patterns, particularly when treatment is started or adjusted. Vaginal or endometrial atrophy, uterine polyps, fibroids, cervical changes and other benign conditions can also cause spotting. Most women evaluated for postmenopausal bleeding will not have endometrial cancer.

Bleeding after menopause can also be the first sign of endometrial cancer. It should not automatically be attributed to estrogen, progesterone, a missed dose, a pellet, a compounded hormone or a recent treatment adjustment without considering whether evaluation is needed.

What Counts as Postmenopausal Bleeding?

Natural menopause is generally recognized after twelve consecutive months without a menstrual period when there is no other explanation for the absence of bleeding.

After that point, postmenopausal bleeding may be very light. It can appear only on toilet tissue, look pink or brown rather than bright red, occur after intercourse, resemble a light menstrual period or happen once and stop.

A new episode should be reported to the clinician managing the woman’s care. The amount of blood does not reliably identify the cause.

Hormone therapy complicates the definition slightly. Women using a planned sequential regimen may have an expected withdrawal bleed. That is different from bleeding that is unexpectedly heavy, prolonged, occurs outside the expected schedule, begins after a previously stable bleed-free period or persists beyond the usual adjustment period.

For more background on the transition from perimenopause into menopause, see Hormone Transitions: Perimenopause, Menopause & Healthy Aging.

Most Causes Are Benign, but Endometrial Cancer Is the Diagnosis We Cannot Miss

Thinning of vaginal or endometrial tissue is a common cause of bleeding after menopause. Polyps, fibroids, cervical disease, infection, trauma and medications can also be responsible.

Endometrial hyperplasia and endometrial cancer are less common, but they are important because postmenopausal bleeding is often the symptom that brings the disease to medical attention. ACOG’s 2026 update notes that approximately 90% of patients diagnosed with endometrial cancer have postmenopausal bleeding.

That does not mean that 90% of women with postmenopausal bleeding have cancer. The relationship runs in the other direction: among women who ultimately have endometrial cancer, bleeding is a very common presenting symptom.

This distinction is reassuring without becoming dismissive. Most bleeding will have another explanation, but prompt evaluation gives clinicians the opportunity to find endometrial disease earlier when it is present.

An Important Change in 2026: ACOG No Longer Relies on Ultrasound Alone for Most Patients

For years, one of the most familiar rules in postmenopausal bleeding was the “4-millimeter rule.”

Older ACOG guidance allowed transvaginal ultrasound to serve as the initial evaluation in many women. If the endometrium was clearly visualized and measured 4 mm or less, the probability of endometrial cancer was considered very low, with a negative predictive value greater than 99%.

ACOG changed that approach in April 2026.

The updated Clinical Practice Update recommends that both transvaginal ultrasonography and endometrial tissue sampling be included in the initial evaluation for most patients with postmenopausal bleeding.

The reason is not that ultrasound suddenly became useless. It remains valuable for evaluating the uterus, endometrial thickness and structural abnormalities. The concern is that relying on ultrasound thickness alone can miss malignant or premalignant disease in some patients.

Recent evidence reviewed by ACOG suggests that 5% to 12% of endometrial cancers may not be diagnosed on initial presentation when older ultrasound-based triage strategies are used.

ACOG particularly highlighted the importance of the change for Black women, who experience disproportionate endometrial-cancer mortality and may develop aggressive cancer subtypes that do not always produce an obviously abnormal ultrasound appearance.

There are still carefully selected situations in which ultrasound alone may be considered initially, including a single episode, an endometrium measuring 4 mm or less, absence of significant cancer risk factors and reliable access to prompt follow-up. That is now the exception rather than the general rule.

So What Does a 4-mm Endometrial Thickness Mean Now?

A clearly visualized endometrium measuring 4 mm or less remains reassuring. What changed is how much reassurance clinicians should ask that number to provide.

Under the previous approach, a thin endometrium could often end the initial evaluation if bleeding stopped. Under the updated 2026 ACOG framework, most women with postmenopausal bleeding should also undergo tissue sampling rather than relying on thickness alone.

The measurement therefore remains clinically useful, but it should not be interpreted as an absolute cancer exclusion test.

Persistent or recurrent bleeding deserves additional investigation regardless of the initial endometrial thickness.

Bleeding on Hormone Therapy Requires Its Own Clinical Context

Menopausal hormone therapy can cause unscheduled bleeding, particularly when treatment is first started or when estrogen or progestogen doses are changed.

Continuous-combined therapy is intended eventually to produce little or no bleeding, but spotting may occur during the initial adjustment period. Sequential hormone therapy intentionally includes a period of progestogen exposure followed by an expected withdrawal bleed.

The British Menopause Society has developed a detailed guideline specifically for unscheduled bleeding on hormone therapy. Its approach is more regimen-specific than the general postmenopausal-bleeding pathway.

For low-risk women, unscheduled bleeding that begins within six months of starting HRT, or persists for up to three months after changing the dose or preparation, can sometimes be approached initially by reviewing and adjusting the HRT regimen rather than immediately moving to invasive testing.

That does not apply when bleeding is heavy or prolonged, significant endometrial-cancer risk factors are present, bleeding begins after a previously stable treatment period or symptoms continue despite appropriate adjustment.

This is why the phrase “bleeding on hormones” is not itself a diagnosis. The regimen, timing and patient matter.

For a broader review of how menopausal hormone therapy should be prescribed and monitored, see Bioidentical Hormone Replacement Therapy: Evidence, Options, and Clinical Judgment.

The 4-mm Threshold and HRT-Specific Ultrasound Thresholds Are Not the Same Rule

This is an area where online explanations can become confusing.

ACOG’s 2026 U.S. guidance addresses the initial evaluation of postmenopausal bleeding broadly and now favors combined ultrasound and tissue sampling for most patients.

The British Menopause Society guideline specifically addresses women with unscheduled bleeding while using hormone replacement therapy.

In a woman with unscheduled bleeding whose endometrium is uniform and fully visualized, the BMS considers the risk of endometrial cancer low when the lining measures:

• 4 mm or less with continuous-combined HRT, or
• 7 mm or less with sequential HRT.

When those thresholds are exceeded, the BMS recommends referral for endometrial assessment, which may include biopsy and/or hysteroscopy.

These thresholds belong to an HRT-specific pathway. They should not be taken out of context and used to override updated U.S. guidance for spontaneous postmenopausal bleeding.

Estrogen, Progesterone, and the Uterine Lining

Estrogen stimulates the endometrium, the tissue lining the inside of the uterus. During reproductive life, progesterone counterbalances that stimulation after ovulation and helps regulate endometrial growth.

After menopause, a woman who still has a uterus and uses systemic estrogen generally needs adequate progesterone or another effective progestogen to reduce the risk of endometrial hyperplasia and cancer.

The important word is adequate.

Protection depends on the estrogen dose, the progesterone or progestogen used, the route, schedule, duration and adherence. The progestogen dose should also be proportionate to the estrogen exposure.

Simply putting progesterone somewhere in the prescription does not automatically establish that the uterus is protected.

This is discussed in greater detail in Progesterone Is Not Just “The Sleep Hormone”.

Progesterone Cream Is Not Reliable Endometrial Protection

Transdermal progesterone creams have not demonstrated sufficiently reliable endometrial protection for women using systemic estrogen.

A cream may produce subjective effects or measurable progesterone exposure without delivering consistent protection to the endometrium.

This is particularly important when higher estrogen doses, pellets or compounded hormone regimens are being used. Increasing systemic estrogen while relying on inadequately absorbed progesterone can create a treatment imbalance that a serum hormone number does not resolve.

Women using compounded therapy deserve the same endometrial safety standards as women using commercially manufactured therapy.

“Too Much Estrogen” Is Not Defined by One Blood Level

The phrase “too much estrogen” is often used loosely in hormone medicine.

Serum estradiol can be useful in selected clinical circumstances, but it does not by itself determine how much endometrial stimulation is occurring. Oral, transdermal, vaginal, injectable, implanted and compounded preparations have different pharmacokinetic profiles.

The clinically useful questions are whether the estrogen dose is appropriate for the indication, whether the woman has a uterus, whether endometrial protection is adequate, whether the regimen is being used consistently and whether unexpected bleeding has occurred.

Escalating estrogen simply to reach a laboratory target or pursue an anti-aging claim can expose a woman to unnecessary risk. Hormone therapy is medical treatment, not a competition to achieve a particular estradiol number.

For more context on estradiol and clinical interpretation, see Estradiol, Women’s Health, and Longevity Medicine.

What Proper Hormone-Therapy Monitoring Looks Like

Good hormone care is a follow-up relationship rather than a prescription transaction.

Monitoring is individualized, but it begins with knowing exactly what the patient is taking, how she is taking it and whether she still has a uterus.

Follow-up commonly includes:

• review of bleeding, spotting, discharge, pelvic discomfort and breast symptoms;
• confirmation of estrogen dose, route and treatment schedule;
• confirmation of progestogen dose, route, schedule and adherence;
• review of compounded products, pellets, vaginal preparations and over-the-counter hormone creams;
• assessment of blood pressure, metabolic health, body composition, cardiovascular risk and new medical diagnoses;
• coordination of breast, cervical, bone and other appropriate preventive care;
• laboratory testing when it answers a defined clinical question; and
• pelvic imaging, endometrial sampling or gynecology referral when bleeding or other findings warrant evaluation.

Routine transvaginal ultrasound is not recommended simply as an annual screening test for every asymptomatic woman taking hormone therapy. Once bleeding occurs, however, the question changes from screening to diagnosis.

What Does Transvaginal Ultrasound Show?

Transvaginal ultrasound uses a narrow probe placed in the vagina to obtain detailed images of the uterus, endometrium, ovaries and surrounding structures.

It can measure endometrial thickness and identify findings such as polyps, fibroids, fluid, irregular thickening or an endometrium that cannot be visualized adequately.

Ultrasound remains an important part of evaluating postmenopausal bleeding even though the 2026 ACOG update reduced reliance on ultrasound as a stand-alone triage test.

What Does an Endometrial Biopsy Add?

Endometrial sampling removes tissue from inside the uterus so that a pathologist can look for hyperplasia, precancerous changes or malignancy.

That is information an ultrasound cannot provide directly.

The 2026 ACOG update therefore recommends including tissue sampling in the initial evaluation for most women with postmenopausal bleeding rather than reserving biopsy only for women whose endometrium exceeds 4 mm.

An office biopsy is useful, but it is not perfect. Because the device samples only a portion of the uterine cavity, focal lesions such as polyps or localized areas of abnormal tissue can occasionally be missed.

An inadequate or benign biopsy does not necessarily end the investigation if bleeding persists or recurs.

Why Hysteroscopy May Be Needed

Hysteroscopy allows a gynecologist to pass a small camera through the cervix and inspect the uterine cavity directly.

This is particularly useful when ultrasound suggests a focal lesion, when a biopsy is insufficient or discordant with the clinical picture, or when bleeding persists despite an apparently reassuring initial evaluation.

A polyp or localized abnormality can be visualized and sampled directly rather than depending only on blind tissue sampling.

Dilation and curettage, or D&C, may be performed with hysteroscopy when more complete tissue sampling or treatment is required.

Persistent or Recurrent Bleeding Changes the Conversation

A reassuring first evaluation is useful, but recurrent symptoms matter.

Rare endometrial cancers can occur despite a thin endometrial measurement. A blind biopsy can miss a focal lesion. New pathology can also develop after an earlier evaluation.

Persistent or recurrent bleeding therefore warrants continued assessment rather than repeated reassurance based solely on an earlier ultrasound or biopsy.

Risk Factors That Increase Concern

Endometrial cancer can occur without an obvious risk factor, but several factors increase the likelihood of endometrial hyperplasia or cancer.

• Increasing age
• Obesity, particularly substantial excess adiposity
• Insulin resistance or type 2 diabetes
• Polycystic ovary syndrome or prolonged anovulation
• Prolonged estrogen exposure without adequate progestogen protection
• Tamoxifen use
• Lynch syndrome or another relevant hereditary cancer syndrome
• A personal history of endometrial hyperplasia
• Earlier menarche or later menopause
• Never having carried a pregnancy

The British Menopause Society specifically classifies BMI of 40 or higher and hereditary conditions such as Lynch or Cowden syndrome as major risk factors when evaluating unscheduled bleeding on HRT. BMI of 30 to 39, diabetes and PCOS are among its minor risk factors.

Obesity and insulin resistance deserve attention because adipose tissue contributes to estrogen exposure after menopause, while metabolic dysfunction is associated with endometrial-cancer risk through several pathways.

This is not an argument that a woman caused her bleeding or cancer through her weight. It is an argument for recognizing metabolic health as part of the larger prevention picture. See Metabolic Health and Longevity Medicine.

Vaginal Estrogen Is a Different Clinical Situation

Standard low-dose vaginal estrogen used for genitourinary syndrome of menopause produces much less systemic exposure than systemic estrogen patches, gels, tablets, injections or pellets.

Most women using established low-dose local vaginal estrogen do not require a progestogen solely because of that treatment.

That does not mean bleeding should be ignored. Local estrogen can improve fragile vaginal tissue and may reduce bleeding associated with atrophy, but new postmenopausal bleeding still warrants clinical assessment rather than an assumption that the medication caused it.

Higher-dose vaginal preparations and compounded products may not have the same exposure profile as established low-dose therapies, so the exact product and dose matter.

When Bleeding on HRT Can Sometimes Be Managed With an HRT Adjustment First

This is one of the areas where nuance matters most.

According to the British Menopause Society, a low-risk woman who develops unscheduled bleeding within six months of starting HRT, or within roughly three months of changing the dose or preparation, may sometimes undergo a period of regimen adjustment before urgent imaging is required.

That can include checking adherence, ensuring that the progestogen dose is proportionate to the estrogen dose, modifying the preparation or changing the route.

That approach becomes less appropriate when bleeding is heavy or prolonged, when it begins later after treatment has stabilized, when significant cancer risk factors are present or when bleeding does not improve during the adjustment period.

This is not a contradiction of the principle that postmenopausal bleeding deserves attention. It reflects the fact that expected or early HRT-related bleeding has a different pretest probability and treatment context from spontaneous unexplained bleeding in a woman who is not using HRT.

When to Seek More Urgent Care

Most postmenopausal bleeding can be assessed through timely outpatient care.

More urgent evaluation is appropriate when bleeding is heavy, pads are being soaked rapidly, large clots are being passed, the woman becomes lightheaded or faint, significant abdominal or pelvic pain develops or there are other signs of substantial blood loss or acute illness.

Anticoagulants and medications that increase bleeding should also be reported. These drugs can make bleeding more apparent, but they do not explain where the bleeding originates and should not be used as a reason to skip evaluation.

The HormoneSynergy® Perspective

Properly prescribed menopausal hormone therapy can substantially improve quality of life for appropriately selected women. It remains the most effective treatment for vasomotor symptoms and can provide important benefits for sleep, genitourinary symptoms and bone health.

Those benefits do not require minimizing uterine safety.

A woman with an intact uterus who uses systemic estrogen needs an effective strategy for endometrial protection. She should also understand what bleeding is expected with her regimen, what bleeding should be reported and how an unexpected pattern will be evaluated.

The 2026 ACOG guidance raises the standard of initial evaluation for most postmenopausal bleeding by reducing reliance on ultrasound thickness alone. At the same time, HRT-specific guidance reminds clinicians that not every episode of early treatment-related spotting requires the same pathway.

The useful clinical response is neither hormone fear nor automatic reassurance. It is knowing the regimen, understanding the patient’s risk, protecting the endometrium appropriately and investigating bleeding when the pattern calls for it.

Additional menopause and hormone-therapy education is available through the HormoneSynergy® Longevity Medicine Resource Library.

Frequently Asked Questions

Is one episode of bleeding after menopause enough to call my clinician?

Yes. Even light spotting, pink or brown discharge, or an episode that stops should be reported. The amount or color of bleeding does not reliably identify the cause.

Did the recommendation for evaluating postmenopausal bleeding change in 2026?

Yes. In April 2026, ACOG updated its guidance and recommended that transvaginal ultrasound and endometrial tissue sampling both be included in the initial evaluation for most patients with postmenopausal bleeding. Previous guidance allowed ultrasound alone as the initial test in many women with an endometrial thickness of 4 mm or less.

Does an endometrial thickness of 4 millimeters still rule out cancer?

No measurement completely rules out cancer. A clearly visualized endometrium measuring 4 mm or less remains reassuring, but updated ACOG guidance no longer recommends using that measurement alone to avoid tissue sampling in most patients with postmenopausal bleeding.

Can hormone therapy cause bleeding after menopause?

Yes. Unscheduled bleeding is common during the first months after starting or changing menopausal hormone therapy, and sequential regimens intentionally produce withdrawal bleeding. New, persistent, heavy, recurrent or late-onset bleeding still requires clinical review.

Do women on HRT use the same endometrial-thickness threshold?

Not always. British Menopause Society guidance for unscheduled bleeding on HRT considers a fully visualized endometrium of 4 mm or less low risk with continuous-combined HRT and 7 mm or less with sequential HRT. These HRT-specific thresholds should not be confused with ACOG’s updated general approach to postmenopausal bleeding.

Do I need progesterone if I use estrogen?

A woman with an intact uterus who uses systemic estrogen generally needs adequate progesterone or another effective progestogen to reduce the risk of endometrial hyperplasia and cancer. Women who have had a hysterectomy generally do not need progesterone solely for uterine protection.

Is progesterone cream enough to protect the uterus?

Transdermal progesterone cream is not considered reliable endometrial protection for a woman using systemic estrogen. The molecule, dose, route, schedule and absorption all matter.

Should every woman on hormone therapy have a yearly pelvic ultrasound?

No. Routine transvaginal ultrasound is not generally recommended solely because an asymptomatic woman uses menopausal hormone therapy. The purpose of testing changes once unexpected bleeding develops.

Can a normal endometrial biopsy be the end of the evaluation?

Sometimes, particularly when the tissue sample is adequate and bleeding resolves. Persistent or recurrent bleeding may require hysteroscopy or additional evaluation because blind office sampling can miss focal abnormalities.

When should bleeding on HRT be investigated rather than adjusted?

Evaluation becomes more important when bleeding is heavy or prolonged, begins after a previously stable bleed-free period, persists despite HRT adjustments or occurs in a woman with significant endometrial-cancer risk factors.

Related HormoneSynergy® Resources

• Hormone Transitions: Perimenopause, Menopause & Healthy Aging
• Bioidentical Hormone Replacement Therapy: Evidence, Options, and Clinical Judgment
• Progesterone Is Not Just “The Sleep Hormone”
• Estradiol, Women’s Health, and Longevity Medicine
• Metabolic Health and Longevity Medicine
• HormoneSynergy® Longevity Medicine Resource Library

Selected References

1. American College of Obstetricians and Gynecologists. Updated Guidance Regarding the Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Individuals With Postmenopausal Bleeding. Obstetrics & Gynecology. 2026;148(1):e87-e91.
2. American College of Obstetricians and Gynecologists. ACOG Publishes Updated Guidance on Evaluation of Postmenopausal Bleeding. April 16, 2026.
3. British Menopause Society. Management of Unscheduled Bleeding on Hormone Replacement Therapy. Joint guideline. Reviewed May 2026.
4. Stute P, Neulen J, Wildt L. The Impact of Micronized Progesterone on the Endometrium: A Systematic Review. Climacteric. 2016;19(4):316-328.
5. The Menopause Society. Hormone Therapy.